Infectious Disease Treatment Market

Market Insights

This report on the global infectious disease treatment market studies the increasing demand for infectious disease treatment due to the rise in drug-resistant bacterial strains, early disease diagnosis and treatment, and a promising drug pipeline.

For the purpose of this study, the infectious disease treatment market is segmented into therapeutics (antibacterial drugs, antiviral drugs, antifungal drugs, and antiparasitic drugs) and application type (AIDS, Hepatitis B, Hepatitis C, HPV, MRSA, CT/NG, and others); market size estimates and forecasts for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The pipeline analysis for the global infectious disease treatment market comprises projected market sales of Phase III anti-infective drugs, estimated till 2025. We have estimated sales of very specific molecules based on the type (Imipenem/Cilastatin+Relebactum (MK-7655), S-033188, Cadazolid, Baxdela (Delafloxacin), GS-9620 (TLR-7 agonist), Doravirine (MK-1439), and Zerbaxa (MK-7625A)) of the drugs in the pipeline that is anticipated to be launched during the forecast period.

The global infectious disease treatment market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

Based on therapeutic types, the global infectious disease treatment market is categorized into:

• Antibacterial drugs
• Antiviral drugs
• Antifungal drugs
• Antiparasitic drugs

Factors such as the rising prevalence of infectious disease, technological advancement in the anti-infective drug formulation (e.g., Ciprofloxacin Hydrochloride effervescent tablets have more gastro-retention than Ciprofloxacin Hydrochloride tablets), and rising demand for personalized medication promote the demand for the infectious disease treatment market. Antibacterial drugs hold the largest market due to the increasing prevalence of bacterial infection. A rise in the number of drug-resistant bacterial strains will propel the demand for higher doses of antibiotics.

Antiviral drugs are anticipated to register faster growth due to high public awareness of sexually transmitted diseases such as HIV, HPV, and gonorrhea and technological advancement in the formulation of antivirals with the least side effects, e.g., zidovudine, an antiretroviral drug, is available as an IV formulation to surpass adverse effects such as nausea and vomiting in pregnant women. Overall, the global infectious disease treatment market is highly competitive, with multiple players like Abbott Laboratories, Johnson & Johnson, Hoffman-La Roche AG, Alere, Inc., etc., specializing in their respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the technological advancement in the infectious disease treatment market.

Based on application, the global infectious disease treatment market is categorized into:

• Acquired immunodeficiency syndrome (AIDS)
• Hepatitis B
• Hepatitis C
• Methicillin-resistant Staphylococcus aureus (MRSA) infection acquired in a hospital
• Chlamydia trachomatis and Neisseria gonorrhoea (CT/NG)
• Human Papillomavirus (HPV)
• Others

Human papillomavirus (HPV) held the largest market in the application segment; according to the World Health Organization, approximately 290 million women (1995–2005) suffered from HPV infection. The growth is attributed mainly to the increasing prevalence of HPV infection, high public awareness, and early disease diagnosis. Hospital-acquired Methicillin-resistant Staphylococcus aureus infection (MRSA) will be the fastest growing market due to an increase in the number of MRSA infections in hospitals, medication lapse, unsanitary hospital conditions, use of non-sterile surgical devices, unnecessary antibiotic use, and so on.

For the purpose of this study, the global infectious disease treatment market is categorized into three segments:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

In 2016, North America was identified as the largest market for infectious disease treatment. According to the Centers for Disease Control and Prevention, in 2015, there were about 39,513 new cases of human-acquired immune deficiency syndrome (HIV). The growth is attributed mainly to the increasing prevalence of infectious diseases, increased public awareness, early disease diagnosis, and supportive reimbursement policies. Europe is expected to be the second-largest market due to rising public awareness related to early disease diagnosis, improved healthcare infrastructure, and government and non-government organizations arranging awareness activities and camps.

The growth of the Asia Pacific infectious disease treatment market is attributed to factors like the rising prevalence of infectious disease, increasing investments in drug R&D, and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about health care, and tapping the potential market in remote areas will likely fuel the rapid growth of the infectious disease treatment market in Latin America, the Middle East, and Africa in the near future.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Infectious Disease Treatment Market Portraiture
2.2 Global Infectious Disease Treatment Market, by Therapeutics, 2016 (US$ Mn)
2.3 Global Infectious Disease Treatment Market, by Application, 2016 (US$ Mn)
2.4 Global Infectious Disease Treatment Market, by Geography, 2016 (Value %)

Chapter 3 Global Infectious Disease Treatment Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence of infectious disease
3.2.2 Rising demand for personalized medication
3.3 Market Restraints
3.3.1 The emergence of drug resistant bacterial strains
3.4 Market Opportunities
3.4.1 Technological advancement in the anti-infective drug formulation to achieve more drug efficacy and fewer adverse effects
3.6 Attractive Investment Proposition
3.7 Market Competition Assessment: Infectious Disease Treatment, by Key Players

Chapter 4 Global Infectious Disease Treatment Market, By Therapeutics
4.1 Introduction
4.2 Antibacterial drugs
4.3 Antiviral drugs
4.4 Antifungal drugs
4.5 Antiparasitic drugs
4.6 Projected sales of Phase III drugs estimated till 2025 (US $ Mn)
4.6.1 Imipenem/Cilastatin + relebactum
4.6.2 Cadazolid
4.6.3 GS-9620 (TLR-7 Agonist)
4.6.4 Doravirine (MK-1439)
4.6.5 Others
4.7 Tabular representation of Phase II and I drugs

Chapter 5 Global Infectious Disease Treatment Market, By Application
5.1 Market Analysis
5.2 Acquired Immune Deficiency Syndrome (AIDS)
5.3 Hepatitis B
5.4 Hepatitis C
5.5 Human Papillomavirus
5.6 Hospital acquired Methicillin-resistant Staphylococcus aureus infection (MRSA)
5.7 Chlamydia trachomatis and Neisseria Gonorrhea (CT/NG)
5.8 Others

Chapter 6 Global Infectious Disease Treatment Market, By Geography
6.1 Preface
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Pfizer, Inc.
7.2 F.Hoffman-La Roche AG
7.3 Abbott Laboratories
7.4 Abbvie, Inc.
7.5 Merck & Company
7.6 Alere, Inc.
7.7 Allergan, Inc.
7.8 Bayer AG
7.9 Baxter International Inc.
7.10 Bristol-Myers Squibb Company
7.11 Actelion Pharmaceuticals Ltd.
7.12 Gilead Sciences, Inc.

List of Figures

FIG. 1 Global Infectious Disease Treatment Market: Research Methodology
FIG. 2 Global Infectious Disease Treatment Market, by Therapeutics, 2016 (US$ Mn)
FIG. 3 Global Infectious Disease Treatment Market, by Application, 2016 (US$ Mn)
FIG. 4 Global Infectious Disease Treatment Market, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2016
FIG. 6 Market Positioning of Key Infectious Disease Treatment Vendors, 2016
FIG. 7 Antibacterial Drugs Therapeutic Market, 2015 – 2025 (US$ Mn)
FIG. 8 Antiviral Drugs Therapeutic Market, 2015 – 2025 (US$ Mn)
FIG. 9 Antifungal Drugs Therapeutic Market, 2015 – 2025 (US$ Mn)
FIG. 10 Antiparasitic Drugs Therapeutic Market, 2015 – 2025 (US$ Mn)
FIG. 11 Pipeline Analysis: Global Imipenem/Cilastatin + relebactum Market, Upto 2025 (US$ Mn)
FIG. 12 Pipeline Analysis: Global Cadazolid Market, Upto 2025 (US$ Mn)
FIG. 13 Pipeline Analysis: Global GS-9620 (TLR-7 Agonist) Market, Upto 2025 (US$ Mn)
FIG. 14 Pipeline Analysis: Global Doravirine (MK-1439) Market, Upto 2025 (US$ Mn)
FIG. 15 Pipeline Analysis: Global Others Market, Upto 2025 (US$ Mn)
FIG. 16 Acquired Immune Deficiency Syndrome, Application Market, 2015 – 2025 (US$ Mn)
FIG. 17 Hepatitis B Application Market, 2015 – 2025 (US$ Mn)
FIG. 18 Hepatitis C Application Market, 2015 – 2025 (US$ Mn)
FIG. 19 Human Papillomavirus Application Market, 2015 – 2025 (US$ Mn)
FIG. 20 MRSA Application Market, 2015 – 2025 (US$ Mn)
FIG. 21 CT/NG Application Market, 2015 – 2025 (US$ Mn)
FIG. 22 Others Application Market, 2015 – 2025 (US$ Mn)
FIG. 23 Latin America Infectious Disease Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 24 Middle East and Africa Infectious Disease Treatment Market , 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Infectious Disease Treatment Market, By Therapeutic, 2015-2025 (US$ Mn)
TABLE 2 Global Infectious Disease Treatment Market, By Application, 2015-2025 (US$ Mn)
TABLE 3 Global Infectious Disease Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Global Infectious Disease Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Global Infectious Disease Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Asia-Pacific Global Infectious Disease Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Pfizer, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 8 F.Hoffman-La Roche AG : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 9 Abbott Laboratories : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 10 Abbive, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 11 Merck & Company : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 12 Alere, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 13 Allergan, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 14 Bayer AG : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 15 Baxter International Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 16 Bristol-Myers Squibb Company : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 17 Actelion Pharmaceuticals, Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 18 Gilead Sciences, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)